Uric acid

Cell experiment:

Human colon carcinoma cells (Caco-2) are used and grown in Eagle’s minimum essential medium supplemented with 10% FBS, 1% non-essential amino acid mixture, and 1% Pen-Strep at 37°C in a humidified atmosphere with 5% CO2. Caco-2 cells are incubated with indomethacin in the presence or absence of Uric acid for 24 or 48 hours[1].

Animal experiment:

To evaluate the effect of oral administration of Uric acid on NSAID-induced enteropathy, mice are given Uric acid (2.5, 10, 25, 100, or 250 mg/kg body weight) suspended in 0.5% carboxymethyl cellulose orally at 30 minutes before, and 12 hours after indomethacin or vehicle treatment. To evaluate the effect of intraperitoneal administration of inosinic acid plus potassium oxonate on NSAID-induced enteropathy, mice are given inosinic acid (500 mg/kg body weight) plus potassium oxonate (250 mg/kg body weight) 24 intraperitoneally at 30 minutes before, and 12 hours after indomethacin or vehicle treatment[1].

References:

[1]. Yasutake Y, et al. Uric acid ameliorates indomethacin-induced enteropathy in mice through its antioxidant activity. J Gastroenterol Hepatol. 2017 Nov;32(11):1839-1845.